Aryl aniline β2 adrenergic receptor agonists
AssigneeTheravance, Inc.
InventorsEdmund J. Moran, John R. Jacobsen, James Aggen
Life of this patent
Estimating the term…
Abstract
The invention provides novel β2 adrenergic receptor agonist compounds of formula (I): wherein R1–R13 and w have any of the values described in the specification. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
Claims4
A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of N-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(R)-2-hydroxy-2-(8-hydroxy-2-(1H)-quinolinon-5-yl)ethylamine or a pharmaceutically-acceptable salt thereof.
Dependencies are inferred from the claim text.